Accelerated Early Phase Decision-Making – Insider Insights to Speed Development
Access insider insights from combined perspectives of clinical pharmacology, global regulatory considerations, and private equity investors on accelerating early development timelines to go/no go decisions and early proof of concept, without shortcuts. Parexel’s early phase team and EQT LifeSciences share best practices for combining sequential early phase studies into a single protocol.
Related Insights
Blog
3 steps for making your CRO relationships more successful
Jul 29, 2021
Article
How a joined-up development strategy pays off for early-stage biotechs
May 19, 2021
Blog
Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Nov 19, 2021
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Article
Maximize the efficiency of regulatory operations with five key competencies
Jul 23, 2021
Playbook
What emerging trends in the FDA’s most coveted designations might tell us
Feb 8, 2024
Blog
Focusing on value drivers to reduce risk in early-stage drug development
Jan 6, 2025
Video
Overcoming asset transfer challenges during a merger and acquisition (M&A)
Oct 20, 2021
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Blog
Proof of product safety and efficacy: how to move ahead successfully in Phase 2 clinical development
Jan 22, 2025
Blog
Overcoming risks in Phase 3 trials to accelerate time to market
Jan 22, 2025
Article
8 things you need to know about eCTDs in China
Jul 1, 2022
Related Insights
Blog
3 steps for making your CRO relationships more successful
Jul 29, 2021
Article
How a joined-up development strategy pays off for early-stage biotechs
May 19, 2021
Blog
Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Nov 19, 2021
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Article
Maximize the efficiency of regulatory operations with five key competencies
Jul 23, 2021
Playbook
What emerging trends in the FDA’s most coveted designations might tell us
Feb 8, 2024
Blog
Focusing on value drivers to reduce risk in early-stage drug development
Jan 6, 2025
Video
Overcoming asset transfer challenges during a merger and acquisition (M&A)
Oct 20, 2021
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Blog
Proof of product safety and efficacy: how to move ahead successfully in Phase 2 clinical development
Jan 22, 2025
Blog
Overcoming risks in Phase 3 trials to accelerate time to market
Jan 22, 2025
Article
8 things you need to know about eCTDs in China
Jul 1, 2022